Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsWe have established an Omni-Hybridoma™ platform, in which newly fused hybridoma cells are subcloned, grown and selected using an agarose-based semi-solid medium containing growth factors, B-cell stimulators and medium supplements optimized for the growth of single hybridoma cells. This revolutionary platform ensures that a large number of hybridoma clones can be selected after each cell fusion.
In traditional hybridoma plating methods, multiple rounds of limiting dilutions are required to obtain monoclonal hybridoma clones. A serious problem is that some hybridoma clones overgrow others prior to cloning. Often, these faster growing cell lines do not synthesize antibodies, resulting in a failure to obtain the best antibody-producing hybridoma clones. Also, it is extremely labor-intensive and time-consuming to single-cell clone a hybridoma clone by performing multiple rounds of limited dilutions, thus making it difficult to isolate a large number of hybridoma clones from each cell fusion.
The Omni-Hybridoma™ platform is designed to select and clone hybridoma cell clones immediately after fusion. This eliminates the possibility of overgrowth of potentially valuable slow-growing clones by fast-growing clones. In this platform, hybridoma colonies are clonal from the start; the number of clones to be screened for the secretion of a specific antibody is minimized because all daughter cells are found in the same colony. Most importantly, since HAT selection and cloning of hybridomas are performed simultaneously in a single step, large numbers of hybridomas can be selected and tested. In fact, more than 1,500 hybridoma clones can be single-cells cloned in ten 15cm dishes after a single fusion, thus significantly increasing the number of candidate hybridoma clones that are specific for the target immunogen.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
